Burden of Human papillomavirus (HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea

IF 3.2

Papillomavirus Research Pub Date : 2019-06-01 DOI:10.1016/j.pvr.2018.12.002

Young-Tak Kim , Beatriz Serrano , Jae-Kwan Lee , Hyunju Lee , Shin-Wha Lee , Crystal Freeman , Jin-Kyoung Oh , Laia Alemany , Francesc-Xavier Bosch , Laia Bruni

{"title":"Burden of Human papillomavirus (HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea","authors":"Young-Tak Kim , Beatriz Serrano , Jae-Kwan Lee , Hyunju Lee , Shin-Wha Lee , Crystal Freeman , Jin-Kyoung Oh , Laia Alemany , Francesc-Xavier Bosch , Laia Bruni","doi":"10.1016/j.pvr.2018.12.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>We aimed to review the burden and the potential impact of human papillomavirus (HPV) vaccines on HPV-related diseases in the Republic of Korea and to discuss cervical cancer prevention practices in this country.</p></div><div><h3>Methods</h3><p>Cancer burden statistics were retrieved from GLOBOCAN-2018 and Statistics Korea. HPV disease burden was assessed via systematic review. Vaccine types relative contribution (RC) was estimated using data from an international project using formalin-fixed paraffin-embedded specimens.</p></div><div><h3>Results</h3><p>Despite a downtrend in cervical cancer in recent years, Korean rates remain high. In contrast, oropharyngeal cancer incidence has gradually increased and other anogenital cancers remain rare.</p><p>In Korea, HPV prevalence in general population is around 20%. In cervical cancer, RC of HPVs 16/18 (74.0%) increased to 92.0% when including HPVs 31/33/45/52/58. Limited information was available for other HPV-related cancer sites.</p><p>Regarding prevention, since the inclusion of the HPV vaccine into the National Immunization Program, almost half (49%) of the target cohort in 2016 had received the first dose of vaccine. Further, percentage of women screened with pap has increased from 41.1%-2009 to 53.0%-2016.</p></div><div><h3>Conclusions</h3><p>HPV-related disease burden in Korea is significant. Results suggest that the combination of effective and high coverage HPV vaccination and screening programmes could substantially impact on HPV-related disease in Korea.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.12.002","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Papillomavirus Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405852118300211","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 13

Abstract

Background

We aimed to review the burden and the potential impact of human papillomavirus (HPV) vaccines on HPV-related diseases in the Republic of Korea and to discuss cervical cancer prevention practices in this country.

Methods

Cancer burden statistics were retrieved from GLOBOCAN-2018 and Statistics Korea. HPV disease burden was assessed via systematic review. Vaccine types relative contribution (RC) was estimated using data from an international project using formalin-fixed paraffin-embedded specimens.

Results

Despite a downtrend in cervical cancer in recent years, Korean rates remain high. In contrast, oropharyngeal cancer incidence has gradually increased and other anogenital cancers remain rare.

In Korea, HPV prevalence in general population is around 20%. In cervical cancer, RC of HPVs 16/18 (74.0%) increased to 92.0% when including HPVs 31/33/45/52/58. Limited information was available for other HPV-related cancer sites.

Regarding prevention, since the inclusion of the HPV vaccine into the National Immunization Program, almost half (49%) of the target cohort in 2016 had received the first dose of vaccine. Further, percentage of women screened with pap has increased from 41.1%-2009 to 53.0%-2016.

Conclusions

HPV-related disease burden in Korea is significant. Results suggest that the combination of effective and high coverage HPV vaccination and screening programmes could substantially impact on HPV-related disease in Korea.

Abstract Image

查看原文本刊更多论文

韩国人乳头瘤病毒(HPV)相关疾病的负担和HPV疫苗的潜在影响

背景:我们旨在回顾韩国人乳头瘤病毒(HPV)疫苗对HPV相关疾病的负担和潜在影响，并讨论该国的宫颈癌预防措施。方法癌症负担统计数据来源于GLOBOCAN-2018和韩国统计局。通过系统评价评估HPV疾病负担。使用福尔马林固定石蜡包埋标本的国际项目数据估计疫苗类型相对贡献(RC)。结果尽管近年来宫颈癌发病率呈下降趋势，但韩国的宫颈癌发病率仍然很高。相比之下，口咽癌的发病率逐渐增加，而其他肛门生殖器官癌症仍然罕见。在韩国，HPV在一般人群中的患病率约为20%。在宫颈癌中，当包括hpv 31/33/45/52/58时，hpv 16/18的RC从74.0%增加到92.0%。其他hpv相关癌症部位的信息有限。在预防方面，自将HPV疫苗纳入国家免疫规划以来，2016年几乎一半(49%)的目标队列接受了第一剂疫苗。此外，接受pap筛查的女性比例从2009年的41.1%增加到2016年的53.0%。结论韩国shpv相关疾病负担显著。结果表明，有效和高覆盖率的HPV疫苗接种和筛查规划的结合可能对韩国HPV相关疾病产生重大影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Papillomavirus Research VIROLOGY-

自引率

0.00%

发文量

审稿时长

14 weeks

期刊介绍： The official Journal of the International Papillomavirus Society Papillomavirus Research (PVR), the Journal of HPV and other Small DNA Tumor Viruses publishes innovative papers related to all aspects of papillomaviruses and other small DNA tumor viruses. The official journal of the International Papillomavirus Society, PVR is an open access publication that aims to bring together virologists, immunologists, epidemiologists and clinicians working in the booming field of HPV and animal papillomaviruses, polyomaviruses and other small DNA tumor viruses and their associated diseases, in order to foster and facilitate interdisciplinary communication. The journal welcomes original research articles, reviews, short communications, opinion articles and regional update reports on papillomaviruses and other tumor viruses in the following sections: a. Biology of papillomaviruses and related viruses from life cycle to cancer b. Epidemiology etiology and natural history studies c. Natural and induced immunity including vaccine research d. Intervention studies and strategies including i. Clinical studies and trials ii. HPV treatments iii. HPV vaccination programs iv. Diagnostics and screening e. Infection and disease prevention, modeling studies f. Guidelines and public health recommendations g. HPV Studies in special populations Regional and local studies on these viruses.